Achillion: UBS Global Healthcare Conference (Achillion) - May 25, 2014 - "ACH-3102 + Sovaprevir + RBV Phase 2 Study"; "Achieved 100% SVR24 in GT1b Patients"; "100% of GT1b patients achieved SVR24 despite the presence of baseline RAVs, including the Y93H mutation in NS5A"
P2 data • Hepatitis C Virus
|